Physician profile
Bridget M Wright
NPI 1861506768
$18,672.47
in general payments reported to CMS, 2019-2025
40 companies · $2,706 in 2025
The $2,706 reported for 2025 was more than what 75% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,887 · 2020: $1,612 · 2021: $2,704 · 2022: $2,808 · 2023: $2,875 · 2024: $3,080 · 2025: $2,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,572 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,572.22 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,199.82 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,711.01 | 2019-2025 | Enbrel, Tavneos, Krystexxa |
| Ucb, INC. | $2,264.70 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,474.50 | 2019-2025 | |
| Janssen Biotech, INC. | $1,394.84 | 2019-2025 | Tremfya, Simponi Aria |
| Aurinia Pharma U.S., INC. | $1,063.84 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $990.45 | 2019-2023 | Krystexxa |
| Pfizer INC. | $940.64 | 2019-2025 | |
| Glaxosmithkline, LLC. | $764.90 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $456.66 | 2022-2025 | Saphnelo |
| Genzyme Corporation | $438.57 | 2019-2025 | |
| Lilly USA, LLC | $397.59 | 2019-2024 | Taltz |
| Genentech USA, INC. | $258.58 | 2019-2024 | Actemra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.05 | 2019-2024 | Ofev, Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $190.22 | 2019-2025 | Orencia |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $184.67 | 2020-2024 | Acthar |
| Celgene Corporation | $181.13 | 2019 | |
| Antares Pharma, INC. | $171.13 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $159.14 | 2019-2023 | Mitigare |
| Medexus Pharma, INC. | $145.35 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $123.95 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $115.99 | 2021-2025 | Strensiq |
| Organon LLC | $114.17 | 2023-2025 | Renflexis, Hadlima |
| Radius Health, INC. | $84.68 | 2019-2024 | Tymlos |
| Mallinckrodt Enterprises LLC | $81.03 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $63.87 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $58.98 | 2022-2025 | Purified Cortrophin Gel, Sovuna |
| Csl Behring | $54.39 | 2025 | Hizentra |
| Sandoz INC. | $53.55 | 2024 | Hyrimoz |
| Fresenius Kabi USA, LLC | $52.99 | 2023-2025 | Tyenne |
| Scilex Pharmaceuticals INC. | $48.45 | 2024-2025 | |
| Zyla Life Sciences, INC. | $40.43 | 2019 | |
| Octapharma USA, INC. | $34.02 | 2023 | Octagam Immune Globulin (Human) |
| Takeda Pharmaceuticals U.S.A., INC. | $30.49 | 2025 | Cuvitru |
| Merck Sharp & Dohme LLC | $25.34 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $25.05 | 2019-2021 | |
| Kyowa Kirin, INC. | $23.00 | 2024 | Crysvita |
| Janssen Pharmaceuticals, INC | $21.78 | 2025 | Tremfya |
| Pharmacosmos Therapeutics INC. | $16.06 | 2022 | |
| Roche Diagnostics Corporation | $14.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.